Fedratinib for patients with myelofibrosis

Ruben Van Dijck; John John Schnog; Peter te Boekhorst

doi:10.1016/s2352-3026(24)00398-3

Fedratinib for patients with myelofibrosis

Ruben Van Dijck^*
, John John Schnog
, Peter te Boekhorst

^*Corresponding author for this work

Hematology

Curacao Medical Center
Curaçao Biomedical and Health Research Institute

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

14 Downloads (Pure)

Original language	English
Article number	e240
Journal	The Lancet Haematology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/s2352-3026(24)00398-3
Publication status	Published - Apr 2025

Access to Document

10.1016/s2352-3026(24)00398-3

Fedratinib for patients with myelofibrosisFinal published version, 45 KBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{adc247c1050243148b536e54419296d2,

title = "Fedratinib for patients with myelofibrosis",

author = "\{Van Dijck\}, Ruben and Schnog, \{John John\} and \{te Boekhorst\}, Peter",

year = "2025",

month = apr,

doi = "10.1016/s2352-3026(24)00398-3",

language = "English",

volume = "12",

journal = "The Lancet Haematology",

issn = "2451-9960",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - Fedratinib for patients with myelofibrosis

AU - Van Dijck, Ruben

AU - Schnog, John John

AU - te Boekhorst, Peter

PY - 2025/4

Y1 - 2025/4

UR - https://www.scopus.com/pages/publications/105001231504

U2 - 10.1016/s2352-3026(24)00398-3

DO - 10.1016/s2352-3026(24)00398-3

M3 - Comment/Letter to the editor

C2 - 40174994

AN - SCOPUS:105001231504

SN - 2451-9960

VL - 12

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 4

M1 - e240

ER -

Fedratinib for patients with myelofibrosis

Access to Document

Other files and links

Cite this